Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin
Portfolio Pulse from
Oramed has announced a joint venture to form OraTech Pharmaceuticals Inc., focusing on oral drug delivery. Oramed shareholders will have a stake in OraTech, which plans to go public on Nasdaq. OraTech will market Oramed's oral protein delivery technology globally.
February 11, 2025 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oramed is forming a new company, OraTech Pharmaceuticals, to focus on oral drug delivery. Oramed shareholders will receive a stake in OraTech, which plans to list on Nasdaq.
The formation of OraTech Pharmaceuticals is a significant strategic move for Oramed, potentially increasing its market reach and value. The plan to list OraTech on Nasdaq could attract investor interest, positively impacting Oramed's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100